European Union: Advocate General's Opinion Concerning the EU Harmonised Test For Granting An Extension Of The Term Of A Patent For Medicinal Products

Last Updated: 29 July 2011
Article by Sangeeta Puran and Sarah Byrt

Originally published 22 July 2011

Keywords: advocate general, EU harmonised test, extension of term, patent, medicinal products, supplementary protection certificates, SPCs

The Advocate General has delivered her advisory opinion on questions referred to the European Court of Justice seeking clarification on the conditions for obtaining supplementary protection certificates ("SPCs") for medicinal products marketed in EU Member States. The references are from the following UK proceedings: Medeva BV v Comptroller-General of Patents, Designs and Trade Marks (case C-322-10) and Georgetown University, University of Rochester, Loyola University of Chicago v Comptroller-General of Patents, Designs and Trade Marks (Case C-422/10).

The questions referred to the ECJ consider the conditions for the grant of an SPC set out under Articles 3(a) and 3(b) of Council Regulation (EC) No. 469/2009 concerning the supplementary protection certificate for medicinal products (the "SPC Regulation"). The key question on which EU harmonisation is sought, is whether Articles 3(a) and 3(b) allow the grant of an SPC for medicinal products comprising active ingredients that are only partially disclosed or claimed in the patent whose term is effectively sought to be extended through the SPC framework.

The reference also asked the ECJ to consider the conditions governing the grant of an SPC for a multi-disease vaccine comprising multiple antigens, including where only one antigen is protected by the patent of interest. The questions relating to vaccines stem from a background where vaccine manufacturers are effectively required by government policy to aim towards large combinations of vaccines wherever possible. The concern by relevant vaccine manufacturers is that, on the application of the narrow test that has been applied to date in the UK to determine whether relevant conditions for the grant of an SPC have been satisfied, no SPC can ever be granted for multi-disease vaccines even though such vaccines require costly investment before marketing authorisation for these vaccines is obtained.

The Advocate General's opinion in effect dismisses the broader "infringement test" argued by the vaccine manufacturer claimant in the underlying Medeva proceedings. Her approach regarding whether relevant conditions for the grant of an SPC have been met supports the narrow test that has been applied to date in the UK. In addition to the specific concerns raised by vaccine manufacturers, it has been argued more generally, that the application of such a test is less favourable to an SPC applicant whose medicinal products comprise active ingredients that are only partially disclosed or claimed in the patent whose term is sought to be extended through the SPC framework. The opinion of the Advocate General is advisory only and the ECJ will not necessarily follow the Advocate General's opinion. The ECJ will now deliberate and deliver its ruling, which may take several weeks. The ECJ's ruling will clearly be of great importance to both drug companies facing much publicised patent expiries for blockbuster drugs, and their competitors keen to enter the market.

For further information on the SPC framework and the Advocate General's opinion, please see below.

The SPC system

The SPC Regulation establishes for the EU a system for effectively extending the patent term of a national patent or European patent for medicinal products through the grant of SPCs. The system recognises that a patentee loses significant periods of its 20 year patent term due to the time it takes to obtain marketing authorisation for a new medicinal product and an extension is justified in the interests of facilitating effective patent protection sufficient to cover the investment made in developing such product.

The SPC Regulation provides that SPCs are to be granted for a product protected under patent law and an SPC confers the same rights as conferred by the "basic patent" protecting the product. The duration of the protection granted by an SPC is such that the holder of both such a basic patent and an SPC is entitled to an overall maximum of 15 years of protection from the time the medicinal product in question first obtains authorisation to be placed on the market in the EU. An SPC, however, cannot be granted for a period exceeding 5 years from the date on which the SPC takes effect1. This 5 year period can be extended for a further period of 6 months where a medicinal product has been tested for paediatric use2.

Articles 3(a) and 3(b) of the SPC Regulation

Article 3 of the SPC Regulation sets out the conditions for obtaining an SPC and the reference to the ECJ concerns two of these conditions, namely the conditions set out in Articles 3(a) and 3(b) of the SPC Regulation. Under these conditions, an SPC can only be granted if in the Member State in which the SPC application is made and at the date of the SPC application:

  • the product for which the SPC is sought (the "SPC Product") is protected by a "basic patent" in force (Article 3(a)); and
  • a valid authorisation to place the SPC Product on the market as a medicinal product has been granted (Article 3(b)).

Determining whether an SPC application satisfies these conditions requires identifying the following: (i) the SPC Product; (ii) the basic patent as required by Article 3(a); and (iii) the medicinal product covered by the valid authorisation as required by Article 3(b).

The questions referred to the ECJ and the Advocate General's opinion

Question 1 - What is meant in Article 3(a) of the SPC Regulation by "the product is protected by a basic patent in force" and what are the criteria for deciding this?

This question arises where there is mismatch between the SPC Product and the nominated "basic patent". In particular, where the SPC Product contains active ingredients not described or claimed in the nominated basic patent, can such a patent be the basic patent for the purposes of Article 3(a) and enjoy the benefit of patent term extension offered by the SPC system? By way of example, the particular mismatch that has arisen in the Medeva proceedings is as follows:

  • The basic patent that Medeva relies on discloses a method for preparing a vaccine by mixing an antigen referred to as pertactin with another antigen, the filamentous haemagglutinin antigen. In general terms, antigens mimic the disease-causing agent of interest and induce the immune response critical to the mechanism by which vaccines improve immunity.
  • Medeva is seeking SPCs to cover vaccine products aimed at the following 5 diseases: diphtheria, tetanus, pertussis, polio and haemophilus influenza type B (a cause of meningitis).
  • In certain of the SPC applications made by Medeva, the relevant SPC Product contains active substances in addition to those described in the subject matter of the Medeva patent. For example, one such SPC Product (SPC1 09/015) is a vaccine that contains the following additional antigens: diphtheria toxoid, tetanus toxoid, pertussis toxoid, inactivated poliovirus type 1, inactivated poliovirus type 2, inactivated poliovirus type 3, haemophilus influenza type b capsular polysaccharide, pertussis fimbrial agglutinogens 2 and 3, and haemophilus influenza type B polyribosylribotol phosphate.

The general issue, as has been considered in the UK, is whether the words "protected by a basic patent in force" in Article 3(a) mean that (i) the SPC Product is disclosed and claimed by the basic patent or (ii) the manufacture or supply of the product would infringe the basic patent ((ii) is known as the "Infringement Test"). Of these tests, the Infringement Test is more favourable to an SPC applicant whose basic patent covers only part of the underlying active ingredients of the SPC Product because such a basic patent, by virtue of claiming only part of the active ingredients (or in the case of a vaccine, only part of the antigens), could prevent the sale of a product that uses a combination of active ingredients (or a vaccine that includes other antigens), even though not the subject-matter of the basic patent.

The Advocate General's opinion dismisses the application of the Infringement Test. She partly arrives at this view on the basis of her interpretation of the terms "product" and "basic patent" as defined in the SPC Regulation. The SPC Regulation provides that SPCs are granted for a product protected under patent law. A product is defined as "the" active ingredient or combination of active ingredients of a medicinal product. The Advocate General considers this definition to encompass the whole active or effective part of the medicinal product and, in the case of a medicinal product with multiple active ingredients, the combination of all the active ingredients constitute the "product" and for the grant of an SPC, a product must form the subject matter of a "basic patent".

Although not phrasing the distinction between the 2 tests in the same way as described above, the Advocate General considers that the correct test should be to establish which active ingredients are protected by a patent under national law (i.e. asking the question what is the subject matter of the patent) and not which forms of commercial activity the patent proprietor can prohibit third parties from engaging in (i.e. asking the question what is the protective effect of the patent). The question of whether a medicinal product forms the subject matter of a national or European patent must be answered on the basis of the national rules governing that patent.

Questions 2 and 3 - Should a different test be applied in cases where the product is a medicinal product comprising multiple active ingredients or where the product is a multi-disease vaccine?

The Advocate General's opinion is that there are no further or different criteria in the case of a medicinal product comprising more than one active ingredient or, where the product is a multi-disease vaccine, for the purposes of Article 3(a).

Questions 4 and 5 - For the purposes of Article 3(a), is a multi-disease vaccine comprising multiple antigens "protected by a basic patent" if one antigen of the vaccine is "protected by the basic patent in force"? For the purposes of Article 3(a), is a multi-disease vaccine comprising multiple antigens "protected by a basic patent" if all antigens directed against one disease are "protected by the basic patent in force"?

The Advocate General's opinion is that these questions must be answered according to the rules governing the basic patent. However, the protective effect of the basic patent must not be used as a criterion for the purposes of answering the question of whether a product within the meaning of Article 3(a) exists.

Question 6 - Does the SPC Regulation and, in particular, Article 3(b), permit the grant of an SPC for a single active ingredient or combination of active ingredients where:

  1. a basic patent in force protects the single active ingredient or combination of active ingredients within the meaning of Article 3(a) of the Regulation; and
  2. a medicinal product containing the single active ingredient or combination of active ingredients together with one or more other active ingredients is the subject of a valid authorisation which is the first marketing authorisation that places the single active ingredient or combination of active ingredients on the market?

This question stems from the scenario where the marketing authorisation sought to be relied on for the purposes of Article 3(b) is for a medicinal product that contains active ingredients in addition to the single active ingredient or combination of active ingredients comprising the SPC Product, resulting in a mismatch between the SPC Product and the medicinal product covered by the nominated marketing authorisation. The Advocate General's opinion is that a valid authorisation for the SPC Product exists for the purposes of Article 3(b) where the active ingredient or combination of active ingredients comprising the SPC Product is contained together with one or more other active ingredients in a medicinal product which was the subject of a valid marketing authorisation.

For a complete copy of the opinion, click here.

Learn more about our Intellectual Property and Life Sciences practices.

Visit us at mayerbrown.com

Mayer Brown is a global legal services organization comprising legal practices that are separate entities (the Mayer Brown Practices). The Mayer Brown Practices are: Mayer Brown LLP, a limited liability partnership established in the United States; Mayer Brown International LLP, a limited liability partnership incorporated in England and Wales; Mayer Brown JSM, a Hong Kong partnership, and its associated entities in Asia; and Tauil & Chequer Advogados, a Brazilian law partnership with which Mayer Brown is associated. "Mayer Brown" and the Mayer Brown logo are the trademarks of the Mayer Brown Practices in their respective jurisdictions.

© Copyright 2011. The Mayer Brown Practices. All rights reserved.

This Mayer Brown article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.